Zembala-John Joanna, Wilczek Krzysztof, Tobota Zdzisław, Chodór Piotr, Cieśla Daniel, Jaźwiec Tomasz, Banasiak Waldemar, Stępińska Janina, Kalarus Zbigniew, Opolski Grzegorz, Zembala Marian
Silesian Center for Heart Diseases in Zabrze, Poland; Department of Doctoral Studies, School of Public Health in Bytom, Medical University of Silesia in Katowice, Poland; Kardio-Med Silesia Science and Technology Park, Zabrze, Poland.
3 Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Silesian Center for Heart Diseases, Zabrze, Poland.
Kardiochir Torakochirurgia Pol. 2016 Dec;13(4):309-315. doi: 10.5114/kitp.2016.64870. Epub 2016 Dec 30.
Aortic stenosis (AS) is the most common valvular heart disease in adults in Europe and North America. Management of AS patients depends on accurate diagnosis of the cause and stage of the disease process: the first and definitive therapeutic choice for a growing number of elderly patients with symptomatic AS is surgical treatment. In patients not eligible for surgery, transcatheter aortic valve implantation (TAVI) constitutes a safe and effective alternative. As an innovative, costly method of treatment, it requires however careful monitoring of its course, documenting its early and long-term results, and assessment of its safety and medical-economic cost-effectiveness. A medical registry seems to be an excellent tool to perform such analysis. The aim of this paper is to present the design and rationale for creation of the first National Cardiac-Cardiac Surgical Registry of Percutaneous Aortic Valve Treatment POL-TAVI, to describe its genesis and to highlight its key assumptions and aims. Despite its recent beginnings, the POL-TAVI Registry has already demonstrated its value and usability in monitoring and assessment of TAVI procedures, leading to further improvement and development of this new method in Poland. It constitutes an important and valuable tool for patients, the medical community and the payer.
主动脉瓣狭窄（AS）是欧洲和北美的成年人中最常见的心脏瓣膜疾病。AS患者的治疗取决于对疾病病因和阶段的准确诊断：对于越来越多有症状的老年AS患者，首要且明确的治疗选择是外科手术治疗。对于不符合手术条件的患者，经导管主动脉瓣植入术（TAVI）是一种安全有效的替代方法。然而，作为一种创新且昂贵的治疗方法，它需要仔细监测其过程，记录其早期和长期结果，并评估其安全性和医疗经济成本效益。医学登记处似乎是进行此类分析的绝佳工具。本文的目的是介绍首个国家经皮主动脉瓣治疗心脏心脏外科登记处POL-TAVI的设计和创建理由，描述其起源，并强调其关键假设和目标。尽管POL-TAVI登记处起步较晚，但它已经在监测和评估TAVI手术中展示了其价值和实用性，从而推动了这种新方法在波兰的进一步改进和发展。它对患者、医学界和付款人来说都是一个重要且有价值的工具。
